GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Days Inventory

Spexis AG (XSWX:SPEX) Days Inventory : 0.00 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Spexis AG's Average Total Inventories for the six months ended in Dec. 2023 was CHF0.00 Mil. Spexis AG's Cost of Goods Sold for the six months ended in Dec. 2023 was CHF0.00 Mil.

The historical rank and industry rank for Spexis AG's Days Inventory or its related term are showing as below:

During the past 11 years, Spexis AG's highest Days Inventory was 106.82. The lowest was 106.82. And the median was 106.82.

XSWX:SPEX's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 193.86
* Ranked among companies with meaningful Days Inventory only.

Spexis AG's Days Inventory stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Spexis AG Days Inventory Historical Data

The historical data trend for Spexis AG's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Days Inventory Chart

Spexis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Spexis AG Semi-Annual Data
Dec13 Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Spexis AG's Days Inventory

For the Biotechnology subindustry, Spexis AG's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spexis AG's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spexis AG's Days Inventory distribution charts can be found below:

* The bar in red indicates where Spexis AG's Days Inventory falls into.



Spexis AG Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Spexis AG's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

Days Inventory (A: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

Spexis AG's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

Days Inventory (Q: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Jun. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 2
=0 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spexis AG  (XSWX:SPEX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Spexis AG's Inventory Turnover for the six months ended in Dec. 2023 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Spexis AG's Inventory to Revenue for the six months ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Spexis AG Days Inventory Related Terms

Thank you for viewing the detailed overview of Spexis AG's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Spexis AG (XSWX:SPEX) Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines